scholarly journals First results of computer-enhanced optical diagnosis of bladder cancer

2020 ◽  
Vol 6 (3) ◽  
pp. 246-249
Author(s):  
T. Wittenberg ◽  
R. Hackner ◽  
T. Bocklitz ◽  
C. Krafft ◽  
W. Becker ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Spatial Organization ◽  
Complete Removal ◽  
Fluorescence Lifetime Imaging ◽  
Label Free ◽  
White Light Cystoscopy ◽  
First Results ◽  
Panoramic Images ◽  
Flat Lesions ◽  
Muscle Invasive

AbstractBladder cancer is the sixth leading cancer cause worldwide. Non-muscle invasive tumors can be diagnosed and treated endoscopically. Based on biopsies alone, pathologists cannot determine the spatial organization of specimens, their relationship with each other, or their complete removal. To extend white light cystoscopy as the gold standard for bladder cancer detection, diagnosis and removal of small or flat lesions, new image-based technologies have been investigated. These include a stereo-cystoscope for improved orientation and navigation, computation of 2D and 3D panoramic images for extended visualization and documentation, as well as label-free fiber-based fluorescence-lifetime imaging (FLIM) and Raman-spectroscopy in combination with statistical data analysis. Combining all these technologies, cystoscopy can will be further enhanced to include new diagnostic possibilities.

scholarly journals REVIEW OF DIAGNOSTIC OPPORTUNITIES FOR IMPROVEMENT OF DETECTION OF NON-MUSCLE INVASIVE BLADDER CANCER

InterConf ◽  
2021 ◽  
pp. 796-803
Author(s):  
Ivan Vladanov ◽  
Alexei Plesacov ◽  
Vitalii Ghicavii
Keyword(s):  
Bladder Cancer ◽  
Narrow Band Imaging ◽  
Imaging Techniques ◽  
Meta Analysis ◽  
Photodynamic Diagnosis ◽  
White Light Cystoscopy ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive ◽  
The One

Recently white light cystoscopy (WLC) is the standard method for detection of urothelial cell carcinoma of the bladder. Regarding the problem that on the one hand the sensitivity of WLC is not high enough, and on the other hand it can miss small ‘satellite’ tumors or carcinoma in situ (CIS), other techniques are used. Such techniques are the new imaging by photodynamic diagnosis (PDD) and narrow band imaging (NBI). The both techniques allow very accurate bladder cancer visualization. It is obviously very important to improve diagnostic accuracy and as consequence it increases the quality of resection. Regarding the meta-analysis of several studies, it can be concluded that the new imaging techniques should be applied for a more precise diagnostic, comparing with WLC. Further results of multicentric meta-analysis between these two techniques will stabilize their advantages for concrete clinical indications.

scholarly journals Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4378
Author(s):  
Giorgio I. Russo ◽  
Tamir N. Sholklapper ◽  
Andrea Cocci ◽  
Giuseppe Broggi ◽  
Rosario Caltabiano ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
White Light ◽  
Narrow Band ◽  
Narrow Band Imaging ◽  
Meta Analysis ◽  
Photodynamic Diagnosis ◽  
Muscle Invasive Bladder Cancer ◽  
White Light Cystoscopy ◽  
Muscle Invasive

Despite early detection and regular surveillance of non-muscle invasive bladder cancer (NMIBC), recurrence and progression rates remain exceedingly high for this highly prevalent malignancy. Limited visualization of malignant lesions with standard cystoscopy and associated false-negative biopsy rates have been the driving force for investigating alternative and adjunctive technologies for improved cystoscopy. The aim of our systematic review and meta-analysis was to compare the sensitivity, specificity, and oncologic outcomes of photodynamic diagnosis (PDD) fluorescence, narrow band imaging (NBI), and conventional white light cystoscopy (WLC) in detecting NMIBC. Out of 1,087 studies reviewed, 17 prospective non-randomized and randomized controlled trials met inclusion criteria for the study. We demonstrated that tumor resection with either PDD and NBI exhibited lower recurrence rates and greater diagnostic sensitivity compared to WLC alone. NBI demonstrated superior disease sensitivity and specificity as compared to WLC and an overall greater hierarchical summary receiver operative characteristic. Our findings are consistent with emerging guidelines and underscore the value of integrating these enhanced technologies as a part of the standard care for patients with suspected or confirmed NMIBC.

scholarly journals Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience

2017 ◽  
Vol 89 (1) ◽  
pp. 39
Author(s):  
Vito Lacetera ◽  
Ubaldo Cantoro ◽  
Lorenzo Montesi ◽  
Daniele Cantoro ◽  
Bernardo Cervelli ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Blue Light ◽  
Daily Practice ◽  
High Grade ◽  
White Light Cystoscopy ◽  
Risk Patients ◽  
History Of ◽  
Muscle Invasive ◽  
Or History

Aim: The objective of the present study is to evaluate the diagnostic accuracy of hexylaminolevulinate (HAL) blue light cystoscopy compared with standard white light cystoscopy (WLC) in daily practice. Materials and methods: An observational, comparative, controlled (within patient) study was carried out at our Center. 61 consecutive patients with suspected or confirmed bladder cancer were recruited for the study from January 2008 until January 2015. Patients with suspected bladder cancer (positive cytology with negative WLC) or history of previous high-grade NMIBC or CIS were included in the study. Biopsies/resection of each positive lesion/suspicious areas were always taken after the bladder was inspected under WLC and BLC. Diagnoses of bladder tumor or CIS were considered as positive results, and the presence of normal urothelium in the biopsy specimen as negative result. Results: 61 BLC were performed. 15/61 (24.5%) with suspected initial diagnosis of NMIBC and 46/61 (75.5%) with a history of high-risk non-muscle invasive bladder cancer (NMIBC). We performed a total of 173 biopsies/TURBT of suspicious areas: 129 positive only to the BLC and 44 both positive to WLC and BLC. 84/173 biopsies/TURBT were positive for cancer. All 84 NMIBC were positive to the BLC, while 35/84 were positive to the WLC with a sensitivity of BLC and WLC respectively of 100% and 41.7%. Sensitivity of WLC for highgrade NMIBC and CIS was 34.1% and 39% respectively while sensitivity of BLC for high-grade NMIBC and CIS was 100%. The specificity of the WLC was 79.9% compared to 48.5% of the BLC. The positive predictive value of BLC and WLC were respectively 48% (95% CI: 0.447-0.523) and 79% (95% CI: 0.856-0.734). Conclusions: Our data confirm those reported in the literature: BLC increases the detection rate of NMIBC particularly in high risk patients (history of CIS or high grade). BLC is a powerful diagnostic tool in the diagnosis of bladder cancer if malignancy is suspected (positive urine cytology) and if conventional WLC is negative.

scholarly journals Application of nanotechnology in the diagnosis and treatment of bladder cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yadong Xu ◽  
Cheng Luo ◽  
Jieqiong Wang ◽  
Lingwu Chen ◽  
Junxing Chen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Diagnosis ◽  
Targeted Delivery ◽  
Complete Removal ◽  
Diagnosis And Treatment ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Cancer Management ◽  
Sample Test ◽  
Muscle Invasive

AbstractBladder cancer (BC) is a common malignancy in the genitourinary system and the current theranostic approaches are unsatisfactory. Sensitivity and specificity of current diagnosis methods are not ideal and high recurrence and progression rates after initial treatment indicate the urgent need for management improvements in clinic. Nanotechnology has been proposed as an effective method to improve theranosis efficiency for both non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). For example, gold nanoparticles (AuNPs) have been developed for simple, fast and sensitive urinary sample test for bladder cancer diagnosis. Nanoparticles targeting bladder cancers can facilitate to distinguish the normal and abnormal bladder tissues during cystoscopy and thus help with the complete removal of malignant lesions. Both intravenous and intravesical agents can be modified by nanotechnology for targeted delivery, high anti-tumor efficiency and excellent tolerability, exhibiting encouraging potential in bladder cancer treatment. Photosensitizers and biological agents can also be delivered by nanotechnology, intermediating phototherapy and targeted therapy. The management of bladder cancer remained almost unchanged for decades with unsatisfactory effect. However, it is likely to change with the fast-developed nanotechnology. Herein we summarized the current utility of nanotechnology in bladder cancer diagnosis and treatment, providing insights for the future designing and discovering novel nanoparticles for bladder cancer management. Graphical Abstract

Sign in / Sign up

Export Citation Format

Share Document